Theragnostics, An Issue of PET Clinics
- 1st Edition, Volume 19-3 - June 4, 2024
- Imprint: Elsevier
- Editors: Andrei Iagaru, Heather A. Jacene
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 2 9 2 1 - 6
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 2 9 2 2 - 3
Contains 12 relevant, practice-oriented topics including theragnostics trials; neuroendocrine tumors: diagnostics; prostate-specific membrane antigen: diagnostics; theragnostics:… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quote- Contains 12 relevant, practice-oriented topics including theragnostics trials; neuroendocrine tumors: diagnostics; prostate-specific membrane antigen: diagnostics; theragnostics: post-therapy imaging; fibroblast-activation-protein inhibitors (FAPI) theragnostics; and more.
- Provides in-depth clinical reviews on theragnostics, offering actionable insights for clinical practice.
- Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
In this issue of PET Clinics, guest editors Drs. Andrei Iagaru and Heather A. Jacene bring their considerable expertise to the topic of Theragnostics. Top experts in the field discuss neuroendocrine tumors: beta-labeled peptides; prostate-specific membrane antigen: interpretation criteria, standardized reporting and the use of artificial intelligence; prostate cancer (gastrin-releasing peptide receptor); selective internal radiation therapy; future directions in theragnostics; and more.
Nuclear medicine radiologists
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Forthcoming Issues
- CME Accreditation Page
- Preface
- Alpha and Beta Radiation for Theragnostics
- Key points
- Introduction
- Summary
- Clinics care points
- Neuroendocrine Tumors: Diagnostics
- Key points
- Introduction
- Conventional imaging
- Somatostatin receptor scintigraphy: overview
- 18F-fluoro-d-glucose-PET/computerized tomography imaging
- PET/CT somatostatin receptor scintigraphy in initial evaluation
- PET/CT somatostatin receptor scintigraphy in follow-up evaluation
- Potential pitfalls in interpretation of PET/CT somatostatin receptor scintigraphy
- Somatostatin Receptor PET/MR imaging
- New PET/CT radiotracers for imaging of neuroendocrine neoplasms
- Summary
- Clinics care points
- Alpha-emitter Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors
- Key points
- Introduction
- Preclinical studies
- Clinical trials and current experience
- Future directions
- Summary
- Clinics care points
- Prostate-specific Membrane Antigen: Diagnostics
- Introduction
- Recurrent disease
- Primary tumor staging
- Comment and future directions
- Prostate-specific Membrane Antigen: Interpretation Criteria, Standardized Reporting, and the Use of Machine Learning
- Key points
- Background
- Standardized reporting of prostate-specific membrane antigen targeting positron emission tomography findings
- Technical aspects of machine learning-based tools for prostate-specific membrane antigen targeting positron emission tomography reporting
- Dedicated software solutions for prostate cancer molecular imaging standardized reporting and prostate-specific membrane antigen reporting and data system
- Summary
- Clinics care points
- Prostate-specific Membrane Antigen: Alpha-labeled Radiopharmaceuticals
- Key points
- Introduction
- Prostate-specific membrane antigen
- Alpha-emitting radionuclides for prostate-specific membrane antigen: physics and radiobiology
- Clinical experience with targeted alpha therapy for prostate cancer
- Current evidence for the efficacy of [225Ac]Ac-prostate-specific membrane antigen therapy in metastatic castrate-resistant prostate cancer
- Efficacy of [225Ac]Ac-prostate-specific membrane antigen in the post−[177Lu]Lu-prostate-specific membrane antigen therapy setting
- [225Ac]Ac-prostate-specific membrane antigen: in the prechemotherapy and/or postandrogen deprivation therapy settings
- [225Ac]Ac-prostate-specific membrane antigen: application in the hormone-sensitive setting
- Rechallenge options
- Summary
- Clinics care points
- Prostate Cancer Radioligand Therapy: Beta-labeled Radiopharmaceuticals
- Introduction
- PSMA-based theranostics
- Summary
- Gastrin Releasing Peptide Receptors-targeted PET Diagnostics and Radionuclide Therapy for Prostate Cancer Management: Preclinical and Clinical Developments of the Past 5 Years
- Key points
- Introduction
- The gastrin releasing peptide receptor
- Gastrin releasing peptide receptor-targeting radiopharmaceuticals
- Preclinical reports on gastrin releasing peptide receptor-targeting radiopharmaceuticals for PET imaging and/or radionuclide therapy
- Gastrin releasing peptide receptor-targeting radiopharmaceuticals for prostate cancer targeting in clinical studies
- Future perspectives
- Summary
- Clinics care points
- Treatment Response Imaging in Prostate Cancer
- Key points
- Introduction
- Current Standard of Care (Prostate Cancer Working Group 3 Criteria)
- Role of Advanced Molecular/Metabolic Imaging in Treatment Response
- Response criteria on molecular/metabolic imaging
- Summary
- Clinics care points
- Hepatic Radioembolization: A Multistep Theragnostic Procedure
- Key points
- Introduction
- Microspheres
- Radioembolization
- The evidence for hepatic radioembolization
- Future perspectives
- Summary
- Clinics care points
- Edition: 1
- Volume: 19-3
- Published: June 4, 2024
- Imprint: Elsevier
- No. of pages: 240
- Language: English
- Hardback ISBN: 9780443129216
- eBook ISBN: 9780443129223
AI
Andrei Iagaru
Affiliations and expertise
Nuclear Medicine, Stanford, CA, USAHJ
Heather A. Jacene
Affiliations and expertise
Department of Radiology
Brigham and Women's Hospital
Harvard Medical School